| |
Integrated Efficacy, Pharmacokinetics, and Safety of Glecaprevir/Pibrentasvir in Patients Taking Concomitant Proton Pump Inhibitors and Other Acid-Reducing Drugs
|
| |
| |
Reported by Jules Levin
World Congress of Gastroenterology at ACG 2017, October 13–18, 2017, Orlando, Florida, United States
Steven Flamm1, Rajender Reddy2, Neddie Zadeikis3, Tarek Hassanein4, Bruce R Bacon5, Andreas Maieron6, Stefan Zeuzem7, Marc Bourliere8, Jose L Calleja9, Rajneet K Oberoi3, Chih-Wei Lin3, Sandra Lovell3, Yao Yu3, Dimitri Semizarov3, Federico Mensa3
1Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States; 2University of Pennsylvania, Philadelphia, Pennsylvania, United States; 3AbbVie Inc., North Chicago, Illinois, United States; 4Southern California GI and Liver Centers and Southern California Research Center, Coronado, California, United States; 5Saint Louis University Liver Center, St. Louis, Missouri, United States; 6University Clinics St. Polten/Elisabethinen Hospital, St. Polten, Austria; 7JW Goethe University, Frankfurt, Germany; 8Hopital Saint Joseph, Marseille, France; 9Hospital Universitario Puerta de Hierro/Universidad Autónoma de Madrid, Spain
| |
| |
| |
|
|
|
